Table 3 Comparison of LVEF, hs-TnI and QTc at each time point between non-cardiotoxicity group and cardiotoxicity group.

From: Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer

Parameter

No cardiotoxicity

n = 353

Cardiotoxicity

n = 67

P value

LVEF (%)

Baseline

65.07 ± 2.59

65.36 ± 1.94

0.404

3m

64.67 ± 2.99

63.45 ± 2.57

0.003*

6m

63.87 ± 3.99

61.93 ± 3.16

0.001*

9m

62.17 ± 4.11

59.65 ± 4.84

< 0.001*

12m

61.39 ± 4.01

56.44 ± 4.30

< 0.001*

hsTnI (pg/ml)

Baseline

2.32 ± 3.03

2.61 ± 2.21

0.063

3m

2.33 ± 2.66

3.34 ± 2.69

0.012*

6m

2.41 ± 2.93

3.99 ± 3.16

0.001*

9m

2.78 ± 3.43

4.60 ± 3.40

< 0.001*

12m

2.85 ± 3.87

4.87 ± 3.61

< 0.001*

QTc (ms)

Baseline

405.19 ± 22.27

415.86 ± 34.90

0.002*

3m

410.26 ± 28.94

430.63 ± 36.73

< 0.001*

6m

417.58 ± 37.43

444.42 ± 45.19

< 0.001*

9m

412.96 ± 29.89

440.26 ± 38.15

< 0.001*

12m

414.12 ± 26.97

438.85 ± 42.92

< 0.001*

  1. Significant values are in [bold].
  2. m month.
  3. *P < 0.05.